Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib monotherapy in relapsed or refractory peripheral T/NK-cell lymphoma or cutaneous T-cell lymphoma
2022-501431-16-00Phase 2Completed
- Sponsor
- Yingli Pharma
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of linperlisib in peripheral T-cell lymphoma (PTCL), natural killer/T-cell lymphoma (NKTL), cutaneous T-cell lymphoma (CTCL) and 2 more (2 cohorts), sponsored by Yingli Pharma. Primary endpoints: Overall response rate for PTCL and Overall response rate for CTCL. Started Jan 2023; status: completed.
02
Drugs
linperlisib
03
Conditions
peripheral T-cell lymphoma (PTCL)natural killer/T-cell lymphoma (NKTL)cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2022-501431-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501431-16-00.